Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 6 (June)

1. Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival Observations from the Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis (APRICOT) trial.
   Am Heart J, 155(6): 1039-46. [Abstract] [Full-text]
2. Long-term prognostic factors after thrombolysis for lower limb ischemia.
   J Vasc Surg, 47(6): 1243-50. [Abstract] [Full-text]
3. Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations.
   J Vasc Surg, 47(6): 1292-9. [Abstract] [Full-text]
4. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
   Biotechnol Bioeng, 100(2): 387-96. [Abstract] [Full-text]
5. Upfront chemotherapy and involved-field radiotherapy results in more relapses than extended radiotherapy for intracranial germinomas: modification in radiotherapy volume might be needed.
   Int J Radiat Oncol Biol Phys, 71(3): 667-71. [Abstract] [Full-text]
6. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
   Int J Radiat Oncol Biol Phys, 71(3): 705-9. [Abstract] [Full-text]
7. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy.
   Int J Radiat Oncol Biol Phys, 71(3): 741-7. [Abstract] [Full-text]
8. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.
   Int J Radiat Oncol Biol Phys, 71(3): 725-34. [Abstract] [Full-text]
9. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
   J Clin Neurosci, 15(7): 778-83. [Abstract] [Full-text]
10. A replicable method for blood glucose control in critically Ill patients.
    Crit Care Med, 36(6): 1787-95. [Abstract] [Full-text]
11. The timing of surgical antimicrobial prophylaxis.
    Ann Surg, 247(6): 918-26. [Abstract] [Full-text]
12. Clinical and economic consequences of antibiotic-impregnated cerebrospinal fluid shunt catheters.
    J Neurosurg Pediatrics, 1(6): 444-50. [Abstract] [Full-text]
13. Preparation and characterization of biocompatible oil-loaded polyelectrolyte nanocapsules.
    Nanomedicine, 4(2): 106-14. [Abstract] [Full-text]
14. N-hexanoyl chitosan-stabilized magnetic nanoparticles: enhancement of adenoviral-mediated gene expression both in vitro and in vivo.
    Nanomedicine, 4(2): 146-54. [Abstract] [Full-text]
15. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives.
    Nanomedicine, 4(2): 115-20. [Abstract] [Full-text]
16. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia.
    Pharmacoepidemiol Drug Saf, 17(6): 620-5. [Abstract] [Full-text]
17. Nonviral gene transfection nanoparticles: function and applications in the brain.
    Nanomedicine, 4(2): 89-97. [Abstract] [Full-text]
18. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
    Dis Colon Rectum, 51(6): 868-74. [Abstract] [Full-text]
19. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy.
    Int J Cancer, 123(3): 695-701. [Abstract] [Full-text]
20. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
    Int J Cancer, 123(3): 577-85. [Abstract] [Full-text]
21. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
    J Natl Cancer Inst, 100(11): 773-83. [Abstract] [Full-text]
22. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    J Natl Cancer Inst, 100(11): 805-14. [Abstract] [Full-text]
23. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.
    Clin Infect Dis, 47(1): 102-4. [Abstract] [Full-text]
24. Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza a in adult long-term care facilities.
    Clin Infect Dis, 47(1): 47-52. [Abstract] [Full-text]
25. Efficient gene delivery using chitosan-polyethylenimine hybrid systems.
    Biomed Mater, 3(2): 25013. [Abstract] [Full-text]
26. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
    Breast Cancer Res Treat, 110(1): 127-34. [Abstract] [Full-text]
27. Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study.
    Am J Clin Oncol, 31(3): 280-4. [Abstract] [Full-text]
28. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Am J Clin Oncol, 31(3): 259-63. [Abstract] [Full-text]
29. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Am J Clin Oncol, 31(3): 237-43. [Abstract] [Full-text]
30. Population-based phase I trial of irinotecan and epirubicin.
    Am J Clin Oncol, 31(3): 226-30. [Abstract] [Full-text]
31. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Am J Clin Oncol, 31(3): 219-25. [Abstract] [Full-text]
32. Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma.
    Am J Clin Oncol, 31(3): 209-12. [Abstract] [Full-text]
33. Reasons for declining computerized insulin protocol recommendations: application of a framework.
    J Biomed Inform, 41(3): 488-97. [Abstract] [Full-text]
34. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.
    Curr Opin Oncol, 20(4): 428-32. [Abstract] [Full-text]
35. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat.
    J Androl, 29(4): 408-17. [Abstract] [Full-text]
36. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
    Gynecol Oncol, 109(3): 329-34. [Abstract] [Full-text]
37. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 109(3): 353-8. [Abstract] [Full-text]
38. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Gynecol Oncol, 109(3): 323-8. [Abstract] [Full-text]
39. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Pediatr Infect Dis J, 27(6): 559-61. [Abstract] [Full-text]
40. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study.
    Lancet, 371(9628): 1915-20. [Abstract] [Full-text]
41. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites.
    Nat Biotechnol, 26(6): 685-94. [Abstract] [Full-text]
42. Invited commentary: Postmenopausal unopposed estrogen and breast cancer risk in the Women's Health Initiative--before and beyond.
    Am J Epidemiol, 167(12): 1416-20. [Abstract] [Full-text]
43. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
    Am J Epidemiol, 167(12): 1407-15. [Abstract] [Full-text]
44. Catanionic aggregates formed from drugs and lauric or capric acids enable prolonged release from gels.
    J Colloid Interface Sci, 323(2): 386-94. [Abstract] [Full-text]
45. Photodynamic ablation of a selected rat embryo: a model for the treatment of extrauterine pregnancy.
    Hum Reprod, 23(7): 1491-8. [Abstract] [Full-text]
46. The validity of self-reported prescription medication use among adolescents varied by therapeutic class.
    J Clin Epidemiol, 61(7): 714-7. [Abstract] [Full-text]
47. Differences in the contents of two randomized surveys of GPs' prescribing intentions affected response rates.
    J Clin Epidemiol, 61(7): 718-21. [Abstract] [Full-text]
48. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.
    Clin Infect Dis, 46(12): 1921-5. [Abstract] [Full-text]
49. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?
    Clin Infect Dis, 46(12): 1889-901. [Abstract] [Full-text]
50. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain.
    Clin Infect Dis, 46(12): 1838-43. [Abstract] [Full-text]
51. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
    Cancer, 112(12): 2671-5. [Abstract] [Full-text]
52. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
    Cancer, 112(12): 2720-5. [Abstract] [Full-text]
53. Disease control intervals in high-risk neuroblastoma.
    Cancer, 112(12): 2796-801. [Abstract] [Full-text]
54. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
    Cancer, 112(12): 2733-9. [Abstract] [Full-text]
55. Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines.
    Am J Health Syst Pharm, 65(12): 1180-3. [Abstract] [Full-text]
56. Dual antiplatelet therapy with clopidogrel and aspirin.
    Am J Health Syst Pharm, 65(12): 1134-43. [Abstract] [Full-text]
57. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
    Biol Blood Marrow Transplant, 14(7): 795-8. [Abstract] [Full-text]
58. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    J Control Release, 129(1): 1-10. [Abstract] [Full-text]
59. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme.
    J Control Release, 129(1): 41-8. [Abstract] [Full-text]
60. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
    J Control Release, 129(1): 18-25. [Abstract] [Full-text]
61. Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats.
    J Control Release, 129(1): 33-40. [Abstract] [Full-text]
62. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
    J Control Release, 129(1): 49-58. [Abstract] [Full-text]
63. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia.
    Leukemia, 22(6): 1144-53. [Abstract] [Full-text]
64. Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth.
    Clin Orthop Relat Res, 466(7): 1726-33. [Abstract] [Full-text]
65. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Blood, 111(12): 5509-14. [Abstract] [Full-text]
66. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    J Infect Dis, 198(1): 59-67. [Abstract] [Full-text]
67. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    J Infect Dis, 198(1): 51-8. [Abstract] [Full-text]
68. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Onkologie, 31(6): 315-20. [Abstract] [Full-text]
69. A pilot trial of vascular targeted photodynamic therapy for renal tissue.
    J Urol, 180(1): 338-42. [Abstract] [Full-text]
70. The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China.
    Pediatr Blood Cancer, 51(2): 204-9. [Abstract] [Full-text]
71. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
    Pediatr Blood Cancer, 51(2): 235-40. [Abstract] [Full-text]
72. Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors.
    Biophys J, 95(1): 225-35. [Abstract] [Full-text]
73. Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction.
    Am J Cardiol, 101(12): 1723-8. [Abstract] [Full-text]
74. Impact of hormone replacement therapy on exercise training-induced improvements in insulin action in sedentary overweight adults.
    Metabolism, 57(7): 888-95. [Abstract] [Full-text]
75. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.
    Nat Rev Microbiol, 6(7): 529-40. [Abstract] [Full-text]
76. Targeting of polyamidoamine-DNA nanoparticles using the Staudinger ligation: attachment of an RGD motif either before or after complexation.
    Bioorg Med Chem, 16(13): 6641-50. [Abstract] [Full-text]
77. Antiretroviral therapy of late presenters with advanced HIV disease.
    J Antimicrob Chemother, 62(1): 41-4. [Abstract] [Full-text]
78. Poly(lactic-co-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor.
    Biotechnol Bioeng, 100(5): 1010-9. [Abstract] [Full-text]
79. Nanostructured microspheres produced by supercritical fluid extraction of emulsions.
    Biotechnol Bioeng, 100(5): 1020-33. [Abstract] [Full-text]
80. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    J Clin Oncol, 26(18): 3051-6. [Abstract] [Full-text]
81. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia.
    J Clin Oncol, 26(18): 3025-30. [Abstract] [Full-text]
82. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    J Clin Oncol, 26(18): 2979-83. [Abstract] [Full-text]
83. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
    J Clin Oncol, 26(18): 2959-65. [Abstract] [Full-text]
84. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
    BMC Cancer, 8: 169. [Abstract] [Full-text]
85. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    J Clin Oncol, 26(18): 2966-72. [Abstract] [Full-text]
86. Module assemblage technology for floating systems: in vitro flotation and in vivo gastro-retention.
    J Control Release, 129(2): 88-92. [Abstract] [Full-text]
87. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis.
    J Control Release, 129(2): 100-6. [Abstract] [Full-text]
88. Formulation of rifampicin-cyclodextrin complexes for lung nebulization.
    J Control Release, 129(2): 93-9. [Abstract] [Full-text]
89. Fabrication of nano-fibrous collagen microspheres for protein delivery and effects of photochemical crosslinking on release kinetics.
    J Control Release, 129(2): 135-43. [Abstract] [Full-text]
90. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
    Mol Pharmacol, 74(1): 82-91. [Abstract] [Full-text]
91. Evidence-based emergency medicine/critically appraised topic. Is fluid therapy associated with cerebral edema in children with diabetic ketoacidosis?
    Ann Emerg Med, 52(1): 69-75.e1. [Abstract] [Full-text]
92. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis.
    Am J Respir Crit Care Med, 178(1): 60-73. [Abstract] [Full-text]
93. Multi-dose drug dispensing and inappropriate drug use: A nationwide register-based study of over 700,000 elderly.
    Scand J Prim Health Care, 26(2): 86-91. [Abstract] [Full-text]
94. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study.
    Scand J Prim Health Care, 26(2): 80-5. [Abstract] [Full-text]
95. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Cancer Invest, 26(5): 491-8. [Abstract] [Full-text]
96. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
    Cancer Invest, 26(5): 445-7. [Abstract] [Full-text]
97. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic.
    J Am Acad Dermatol, 59(1): 27-33. [Abstract] [Full-text]
98. A 10-year analysis of venous thromboembolism on the surgical service: the effect of practice guidelines for prophylaxis.
    Surgery, 144(1): 3-11. [Abstract] [Full-text]
99. Identification of suspected fatal adverse drug reactions by paediatricians: a UK surveillance study.
    Arch Dis Child, 93(7): 609-11. [Abstract] [Full-text]
100. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
     Am J Cardiol, 102(1): 6-11. [Abstract] [Full-text]
101. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
     J Cataract Refract Surg, 34(7): 1114-20. [Abstract] [Full-text]
102. Double hydrophilic block copolymers PEO-b-PGA: synthesis, application as potential drug carrier and drug release via pH-sensitive linkage.
     J Biomed Mater Res A, 86(2): 428-38. [Abstract] [Full-text]
103. Maintaining bioactivity of NGF for controlled release from PLGA using PEG.
     J Biomed Mater Res A, 86(2): 420-7. [Abstract] [Full-text]
104. Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning.
     J Biomed Mater Res A, 86(2): 374-85. [Abstract] [Full-text]
105. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin.
     J Biomed Mater Res A, 86(2): 300-10. [Abstract] [Full-text]
106. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.
     Jpn J Clin Oncol, 38(6): 426-31. [Abstract] [Full-text]
107. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?
     Jpn J Clin Oncol, 38(6): 445-50. [Abstract] [Full-text]
108. Unit-based clinical pharmacists' prevention of serious medication errors in pediatric inpatients.
     Am J Health Syst Pharm, 65(13): 1254-60. [Abstract] [Full-text]
109. Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity.
     Stroke, 39(7): 2148-50. [Abstract] [Full-text]
110. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.
     Br J Ophthalmol, 92(7): 936-40. [Abstract] [Full-text]
111. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.
     J Acquir Immune Defic Syndr, 48(3): 281-8. [Abstract] [Full-text]
112. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.
     J Acquir Immune Defic Syndr, 48(3): 263-71. [Abstract] [Full-text]
113. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines.
     Invest Ophthalmol Vis Sci, 49(7): 3158-63. [Abstract] [Full-text]
114. Controlled delivery of 5-chlorouracil using poly(ortho esters) in filtering surgery for glaucoma.
     Invest Ophthalmol Vis Sci, 49(7): 2993-3003. [Abstract] [Full-text]
115. Cooperativity and tunable excited state deactivation: modular self-assembly of depsipeptide dendrons on a Hamilton receptor modified porphyrin platform.
     J Am Chem Soc, 130(26): 8491-501. [Abstract] [Full-text]
116. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?
     Nat Clin Pract Cardiovasc Med, 5(7): 387-95. [Abstract] [Full-text]
117. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
     Trop Med Int Health, 13(7): 870-9. [Abstract] [Full-text]
118. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
     Cancer Invest, 26(6): 624-33. [Abstract] [Full-text]
119. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
     Cancer Invest, 26(6): 610-4. [Abstract] [Full-text]
120. Mid term results of ultrasound guided foam sclerotherapy for complicated and uncomplicated varicose veins.
     Eur J Vasc Endovasc Surg, 36(1): 109-13. [Abstract] [Full-text]
121. Medication-related patient safety incidents in critical care: a review of reports to the UK National Patient Safety Agency.
     Anaesthesia, 63(7): 726-33. [Abstract] [Full-text]
122. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.
     J Virol, 82(14): 7223-30. [Abstract] [Full-text]
123. Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates.
     Br J Clin Pharmacol, 66(1): 128-34. [Abstract] [Full-text]
124. Prophylactic antibiotic use: hardwiring of physician behavior, not education, leads to compliance.
     J Am Coll Surg, 207(1): 88-94. [Abstract] [Full-text]
125. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces.
     Bioinformatics, 24(13): i232-40. [Abstract] [Full-text]
126. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
     Cancer, 113(1): 186-92. [Abstract] [Full-text]
127. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.
     Cancer, 113(1): 108-16. [Abstract] [Full-text]
128. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study.
     Cancer, 113(1): 143-9. [Abstract] [Full-text]
129. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
     Cancer, 113(1): 117-25. [Abstract] [Full-text]
130. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
     Gynecol Oncol, 110(1): 87-92. [Abstract] [Full-text]
131. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.
     Gynecol Oncol, 110(1): 60-4. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.